Breaking Update
CBD Cholesterol Pill Shows Safety and Effectiveness in Israeli Trial
Israeli biotech CannaLean's CLC-01, a CBD-chitosan therapy for high LDL cholesterol, achieved a 28% reduction in a 12-week trial, showing safety and.
Jerusalem, 20 January, 2026 (TPS-IL) — Israeli biotech CannaLean Biotechs announced the successful completion of its first-in-human study of CLC-01, a novel oral cannabidiol–chitosan (CBD–CHT) therapy for high LDL cholesterol. Conducted in partnership with Clalit Health Services, Israel’s largest healthcare organization, the 12-week study showed CLC-01 was well tolerated and led to an average 28% reduction in LDL levels among participants.
“These results validate our platform,” said Chief Scientific Officer Moshe Mittelman. CannaLean plans to advance CLC-01 into larger clinical trials, aiming to provide a safe, accessible alternative for patients who cannot tolerate statins, while exploring broader global commercialization.
